

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

## **REMARKS**

### **(i) Response to Restriction Requirement**

In the Office Action of May 14, 2004, the Examiner restricted the pending claims into patentably distinct inventions according to the following groups:

Group I: Claims 30-36 and 44, drawn to pharmaceutical compositions comprising SC-58215 and oxycodone; and

Group II: Claims 37-43 and 45, drawn to method of treating pain by administering SC-58215 and oxycodone.

In response, Applicants hereby elect, without traverse, Group II, claims 37-43 and 45, drawn to method of treating pain by administering SC-58215 and oxycodone. As Group II is elected, no election of species is necessary according to the Office Action.

The Examiner also requested a chemical structure or STN registry number for 5-(4-fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-Trifluoromethyl 1H Pyrazole. In response, Applicants have attached Appendix A which includes a chemical structure and a CAS registry number for 5-(4-fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-Trifluoromethyl 1H Pyrazole.


Claims 30-36 and 44 have been canceled without prejudice, as they are part of non-elected Group I.

This Response is being submitted withing 30 (thirty) days from the mailing date of the Office Action. Accordingly, it is believed that no fee is due. However, if it is determined that any fee is due, the Examiner is authorized to charge said fee to Attorney Deposit Account No. 50-0552.

An early and favorable action on the merits is earnestly solicited.

Respectfully submitted,  
DAVIDSON, DAVIDSON & KAPPEL, LLC

By: \_\_\_\_\_

  
Robert J. Paradiso  
Reg. No. 41,240

Davidson, Davidson & Kappel, LLC  
485 Seventh Avenue  
New York, New York 10018  
(212) 736-1940



National Library of Medicine  
Specialized Information Services

About • Contact • Search


SIS



ChemIDplus  
Full Record

► [Tox. & Env. Health](#) ► [TOXNET](#) ► [Return to Results Page](#)

SC 58125  
RN: 162054-19-5



#### Names and Synonyms

##### Name of Substance

SC 58125

##### Synonyms

1-((4-Methylsulfonyl)phenyl)-3-trifluoromethyl-5-(4-fluorophenyl)pyrazole  
 SC-58125

##### Systematic Name

1H-Pyrazole, 5-(4-fluorophenyl)-1-(4-(methylsulfonyl)phenyl)-3-(trifluoromethyl)-

#### Formulas

##### Molecular Formula

C<sub>17</sub>-H<sub>12</sub>-F<sub>4</sub>-N<sub>2</sub>-O<sub>2</sub>-S

#### Classification Codes

##### Classification Code

Cyclooxygenase inhibitors

#### Registry Numbers

##### CAS Registry Number

162054-19-5

##### System Generated Number

162054195

#### Locators

##### File Locator

CANCERLIT  
 MEDLINE  
 MESH  
 TOXLINE Core